Johnson & Johnson today said  that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.

The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.

The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.

Related News Articles

Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-…